Scholarlink

Background <p>Neurobrucellosis is a rare but clinically significant complication, accounting for approximately 3–5% of all brucellosis cases. This study aimed to investigate the effect of previous brucellosis treatment on the clinical course, laboratory findings, and treatment response in patients with neurobrucellosis.</p> Methods <p>This multicentre retrospective study included patients diagnosed with neurobrucellosis between January 2014 and December 2024 in nineteen hospitals across Türkiye. Demographic data, clinical symptoms, cerebrospinal fluid findings, serological results, radiological features, treatment regimens, and outcomes were analysed. Patients were divided into two groups based on history of prior brucellosis treatment: previously treated vs. treatment-naive.</p> Results <p>A total of 64 patients (35 male, 29 female; mean age 39.8 ± 14.6 years) were included in the study. 24 (37.5%) had a prior history of brucellosis treatment, while 40 (62.5%) had not received treatment previously. The mean treatment duration was 4.94 ± 3.34 months.The mortality rate was 3.1% (<i>n</i> = 2). Cranial nerve involvement was observed in 17.19% of patients (<i>n</i> = 11). Neuropathy was detected in 7.81% (<i>n</i> = 5), and paralysis in 6.25% (<i>n</i> = 4). Patients with a prior history of brucellosis treatment exhibited markedly lower frequencies of fever (25% vs. 65%, <i>p</i> = 0.005) and neck stiffness (4% vs. 27%, <i>p</i> = 0.023), but significantly higher rates of visual disturbances (62.5% vs. 25%, <i>p</i> = 0.007). CSF protein levels were also significantly higher in previously treated patients (211 vs. 122&#xa0;mg/dL, <i>p</i> = 0.024).</p> Conclusions <p>To our knowledge, this is the first study to evaluate the impact of prior brucellosis treatment on the clinical presentation of neurobrucellosis. Prior brucellosis treatment history may be associated with fewer systemic inflammatory findings, such as fever and neck stiffness, and more frequent visual disturbance at presentation. These findings suggest a potentially modified clinical presentation in previously treated patients. However, given the retrospective design, inter-centre heterogeneity, and the multiple comparisons performed, these findings should be interpreted cautiously. Prospective studies are needed to confirm these observations.</p> Clinical trial registration <p>Not applicable. This study is a retrospective multicentre observational study and does not involve any interventions requiring trial registration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multicentre retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Oğuz Evlice,
  • Ezgi Yılmaz,
  • Murat Hakan Kır,
  • Aysun Benli,
  • Halit Özsüt,
  • Şaban İncecik,
  • Damla Ertürk,
  • Murat Aydın,
  • Ayşe Seza İnal,
  • Yasemin Çakır,
  • Zeliha Karazeybek,
  • Bahar Büşra Sivrikaya,
  • Burak Turaç,
  • Erdal İnci,
  • Sibel Yıldız Kaya,
  • Zeynep Çelik,
  • Ayşe Şabablı Çetin,
  • Işıl Deniz Alıravcı,
  • Sevil Alkan,
  • Özge Özgen Top,
  • Mehmet Çelik,
  • Serkan Sürme,
  • Ali Mert

摘要

Background

Neurobrucellosis is a rare but clinically significant complication, accounting for approximately 3–5% of all brucellosis cases. This study aimed to investigate the effect of previous brucellosis treatment on the clinical course, laboratory findings, and treatment response in patients with neurobrucellosis.

Methods

This multicentre retrospective study included patients diagnosed with neurobrucellosis between January 2014 and December 2024 in nineteen hospitals across Türkiye. Demographic data, clinical symptoms, cerebrospinal fluid findings, serological results, radiological features, treatment regimens, and outcomes were analysed. Patients were divided into two groups based on history of prior brucellosis treatment: previously treated vs. treatment-naive.

Results

A total of 64 patients (35 male, 29 female; mean age 39.8 ± 14.6 years) were included in the study. 24 (37.5%) had a prior history of brucellosis treatment, while 40 (62.5%) had not received treatment previously. The mean treatment duration was 4.94 ± 3.34 months.The mortality rate was 3.1% (n = 2). Cranial nerve involvement was observed in 17.19% of patients (n = 11). Neuropathy was detected in 7.81% (n = 5), and paralysis in 6.25% (n = 4). Patients with a prior history of brucellosis treatment exhibited markedly lower frequencies of fever (25% vs. 65%, p = 0.005) and neck stiffness (4% vs. 27%, p = 0.023), but significantly higher rates of visual disturbances (62.5% vs. 25%, p = 0.007). CSF protein levels were also significantly higher in previously treated patients (211 vs. 122 mg/dL, p = 0.024).

Conclusions

To our knowledge, this is the first study to evaluate the impact of prior brucellosis treatment on the clinical presentation of neurobrucellosis. Prior brucellosis treatment history may be associated with fewer systemic inflammatory findings, such as fever and neck stiffness, and more frequent visual disturbance at presentation. These findings suggest a potentially modified clinical presentation in previously treated patients. However, given the retrospective design, inter-centre heterogeneity, and the multiple comparisons performed, these findings should be interpreted cautiously. Prospective studies are needed to confirm these observations.

Clinical trial registration

Not applicable. This study is a retrospective multicentre observational study and does not involve any interventions requiring trial registration.